1. Home
  2. ZCMD vs COCH Comparison

ZCMD vs COCH Comparison

Compare ZCMD & COCH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Zhongchao Inc.

ZCMD

Zhongchao Inc.

N/A

Current Price

$0.76

Market Cap

2.0M

Sector

Real Estate

ML Signal

N/A

Logo Envoy Medical Inc.

COCH

Envoy Medical Inc.

N/A

Current Price

$0.72

Market Cap

51.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ZCMD
COCH
Founded
2012
1995
Country
China
United States
Employees
N/A
N/A
Industry
Other Consumer Services
Blank Checks
Sector
Real Estate
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
2.0M
51.0M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
ZCMD
COCH
Price
$0.76
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$6.00
AVG Volume (30 Days)
1.2M
40.6K
Earning Date
04-28-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
17.45
EPS
N/A
N/A
Revenue
N/A
$241,000.00
Revenue This Year
N/A
$1.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
7.11
52 Week Low
$0.02
$0.36
52 Week High
$11.96
$1.89

Technical Indicators

Market Signals
Indicator
ZCMD
COCH
Relative Strength Index (RSI) 40.33 48.51
Support Level $0.71 $0.63
Resistance Level $0.79 $0.74
Average True Range (ATR) 0.07 0.04
MACD 0.00 -0.00
Stochastic Oscillator 0.20 35.90

Price Performance

Historical Comparison
ZCMD
COCH

About ZCMD Zhongchao Inc.

ZHONGCHAO Inc is an offshore holding company. Through its subsidiaries, it is a platform-based internet technology company offering services to patients with oncology and other diseases in China. It provides healthcare information, education, and training services to healthcare professionals under its MDMOOC brand. It also provides focused patient management services through the Zhongxun IT system and WeChat mini program, and Zhongxin Health WeChat mini program, to pharmaceutical enterprises and NFP customers.

About COCH Envoy Medical Inc.

Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.

Share on Social Networks: